Merck: priority review for Keytruda in cervical cancer
(CercleFinance.com) - Merck has announced that the US FDA has accepted an additional license application for biologics and has granted a priority review for its Keytruda (pembrolizumab) in the treatment of advanced cervical cancer.
This application, which concerns an expedited authorization of the drug in this new indication, is in part based on data from the current phase II "Keynote-158" trial, which studies it in multiple types of solid advanced tumours.
The pharmaceutical company states that last year, about 12,820 cases of cervical cancer were diagnosed in the US and that the five-year survival rate for women with stage IV disease is estimated at 15% to 16%.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
This application, which concerns an expedited authorization of the drug in this new indication, is in part based on data from the current phase II "Keynote-158" trial, which studies it in multiple types of solid advanced tumours.
The pharmaceutical company states that last year, about 12,820 cases of cervical cancer were diagnosed in the US and that the five-year survival rate for women with stage IV disease is estimated at 15% to 16%.
Copyright (c) 2018 CercleFinance.com. All rights reserved.